Thank you, debbie1956, for sharing this article. From my reading, the main point is that the FDA panel is proposing removing the boxed warning for vaginal (local) estrogen, while the warning for systemic HRT is expected to remain, although risks like breast cancer and cardiovascular disease are more nuanced than older warnings suggested.